TY - JOUR
T1 - Development and validation of a procedure to isolate viable bone marrow cells from the vertebrae of cadaveric organ donors for composite organ grafting
AU - Gorantla, Vijay S.
AU - Schneeberger, Stefan
AU - Moore, Linda R.
AU - Donnenberg, Vera S.
AU - Zimmerlin, Ludovic
AU - Lee, W. P.Andrew
AU - Donnenberg, Albert D.
N1 - Funding Information:
This work was funded in part by the Armed Forces Institute for Regenerative Medicine and the Orthopedic Trauma Research Program and the University of Pittsburgh Medical Center .
PY - 2012/1
Y1 - 2012/1
N2 - Background aims. Donor-derived vertebral bone marrow (BM) has been proposed to promote chimerism in solid organ transplantation with cadaveric organs. Reports of successful weaning from immunosuppression in patients receiving directed donor transplants in combination with donor BM or blood cells and novel peri-transplant immunosuppression has renewed interest in implementing similar protocols with cadaveric organs. Methods. We performed six pre-clinical full-scale separations to adapt vertebral BM preparations to a good manufacturing practice (GMP) environment. Vertebral bodies L4T8 were transported to a class 10 000 clean room, cleaned of soft tissue, divided and crushed in a prototype bone grinder. Bone fragments were irrigated with medium containing saline, albumin, DNAse and gentamicin, and strained through stainless steel sieves. Additional cells were eluted after two rounds of agitation using a prototype BM tumbler. Results. The majority of recovered cells (70.9 ± 14.1%, mean ± SD) were eluted directly from the crushed bone, whereas 22.3% and 5.9% were eluted after the first and second rounds of tumbling, respectively. Cells were pooled and filtered (500, 200 μm) using a BM collection kit. Larger lumbar vertebrae yielded about 1.6 times the cells of thoracic vertebrae. The average product yielded 5.2 ± 1.2 × 10 10 total cells, 6.2 ± 2.2 × 108 of which were CD45+ CD34+. Viability was 96.6 ± 1.9% and 99.1 ± 0.8%, respectively. Multicolor flow cytometry revealed distinct populations of CD34+ CD90+ CD117dim hematopoietic stem cells (15.5 ± 7.5% of the CD34 + cells) and CD45- CD73+ CD105+ mesenchymal stromal cells (0.04 ± 0.04% of the total cells). Conclusions. This procedure can be used to prepare clinical-grade cells suitable for use in human allotransplantation in a GMP environment.
AB - Background aims. Donor-derived vertebral bone marrow (BM) has been proposed to promote chimerism in solid organ transplantation with cadaveric organs. Reports of successful weaning from immunosuppression in patients receiving directed donor transplants in combination with donor BM or blood cells and novel peri-transplant immunosuppression has renewed interest in implementing similar protocols with cadaveric organs. Methods. We performed six pre-clinical full-scale separations to adapt vertebral BM preparations to a good manufacturing practice (GMP) environment. Vertebral bodies L4T8 were transported to a class 10 000 clean room, cleaned of soft tissue, divided and crushed in a prototype bone grinder. Bone fragments were irrigated with medium containing saline, albumin, DNAse and gentamicin, and strained through stainless steel sieves. Additional cells were eluted after two rounds of agitation using a prototype BM tumbler. Results. The majority of recovered cells (70.9 ± 14.1%, mean ± SD) were eluted directly from the crushed bone, whereas 22.3% and 5.9% were eluted after the first and second rounds of tumbling, respectively. Cells were pooled and filtered (500, 200 μm) using a BM collection kit. Larger lumbar vertebrae yielded about 1.6 times the cells of thoracic vertebrae. The average product yielded 5.2 ± 1.2 × 10 10 total cells, 6.2 ± 2.2 × 108 of which were CD45+ CD34+. Viability was 96.6 ± 1.9% and 99.1 ± 0.8%, respectively. Multicolor flow cytometry revealed distinct populations of CD34+ CD90+ CD117dim hematopoietic stem cells (15.5 ± 7.5% of the CD34 + cells) and CD45- CD73+ CD105+ mesenchymal stromal cells (0.04 ± 0.04% of the total cells). Conclusions. This procedure can be used to prepare clinical-grade cells suitable for use in human allotransplantation in a GMP environment.
KW - good manufacturing practice
KW - organ transplantation
KW - vertebral bone marrow
UR - http://www.scopus.com/inward/record.url?scp=82955231986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955231986&partnerID=8YFLogxK
U2 - 10.3109/14653249.2011.605350
DO - 10.3109/14653249.2011.605350
M3 - Article
C2 - 21905958
AN - SCOPUS:82955231986
SN - 1465-3249
VL - 14
SP - 104
EP - 113
JO - Cytotherapy
JF - Cytotherapy
IS - 1
ER -